# Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Study · id `cardio:ct-nct05391893` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05391893](<https://clinicaltrials.gov/study/NCT05391893>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05391893

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 444 participants.

## Technical summary

Registry record NCT05391893. Non-randomized; no masking; primary purpose treatment. Start 2020-06-19 (actual); primary completion 2023-04-01 (actual). Results posted on 2024-12-27.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 444 participants (enrolled count; ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Started: 2020-06-19 (actual) (ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Primary completion: 2023-04-01 (actual) (ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Completion: 2023-04-01 (actual) (ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Results first posted: 2024-12-27 (ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05391893, source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05391893-2024-12-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
- Condition: Atrial Fibrillation
- Condition: Atrial Flutter
- Intervention (Drug): Oral
- Intervention (Drug): Intravenous drug
- Lead sponsor: Corewell Health South
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Atrial flutter (`cardio:atrial-flutter`)

## Provenance

Content hash: 71fa76a41b92f91e95c3e30ce4c86a313bb24141ee61b29fd5d921e60a15172a
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
